Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27649226 | 0.85 | FOLH1 (0.61) | FOLH1MRGPRX4HIF1A | |
| SCHEMBL39676 | 0.84 | TSHR (0.47) | CYP4F2CYP4A11ALDH1A1TSHRFOLH1 | |
| SCHEMBL29472003 | 0.84 | TSHR (0.47) | CYP4F2CYP4A11ALDH1A1TSHRFOLH1 | |
| SCHEMBL5232156 | 0.83 | PARP1 (0.53) | CYP4F2CYP4A11TSHRFOLH1MRGPRX4 | |
| SCHEMBL27447668 | 0.83 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1TSHRFOLH1 | |
| SCHEMBL7138097 | 0.83 | HDAC1 (0.44) | CYP4F2CYP4A11ALDH1A1TSHRFOLH1 | |
| SCHEMBL3892580 | 0.83 | KAT6A (0.50) | CYP4F2CYP4A11ALDH1A1TSHRFOLH1 | |
| SCHEMBL14027395 | 0.83 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1TSHRFOLH1 | |
| SCHEMBL4950108 | 0.82 | ALDH1A1 (0.48) | CYP4F2CYP4A11ALDH1A1TSHRFOLH1 | |
| SCHEMBL15093745 | 0.81 | KEAP1 (0.57) | ALDH1A1FOLH1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304324-B1 | SEROTONIN REUPTAKE INHIBITORS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-6787560-B2 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030191126-A1 | Psychological disorders; antidepressants | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-10-09 | — | — | US | disclosed |
| EP-1304324-A1 | SEROTONIN REUPTAKE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191126-A1 | Psychological disorders; antidepressants | CRH, HTR2C, HTR1A | CYP4F2 491/4885CYP4A11 221/4885ALDH1A1 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.